Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms

Nicolas Hoertel; Marina Sánchez-Rico; Céline Cougoule; Erich Gulbins; Johannes Kornhuber; Alexander Carpinteiro; Katrin Anne Becker; Angela M. Reiersen; Eric J. Lenze; David Seftel; Cédric Lemogne; Frédéric Limosin

doi:10.1038/s41380-021-01254-3

Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms

Nicolas Hoertel, Marina Sánchez-Rico, Céline Cougoule, Erich Gulbins, Johannes Kornhuber, Alexander Carpinteiro, Katrin Anne Becker, Angela M. Reiersen, Eric J. Lenze, David Seftel, Cédric Lemogne, Frédéric Limosin

Research output: Contribution to journal › Letter › peer-review

48 Scopus citations

Original language	English
Pages (from-to)	7098-7099
Number of pages	2
Journal	Molecular Psychiatry
Volume	26
Issue number	12
DOIs	https://doi.org/10.1038/s41380-021-01254-3
State	Published - Dec 2021

Access to Document

10.1038/s41380-021-01254-3

Cite this

Hoertel, N., Sánchez-Rico, M., Cougoule, C., Gulbins, E., Kornhuber, J., Carpinteiro, A., Becker, K. A., Reiersen, A. M., Lenze, E. J., Seftel, D., Lemogne, C., & Limosin, F. (2021). Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms. Molecular Psychiatry, 26(12), 7098-7099. https://doi.org/10.1038/s41380-021-01254-3

@article{2277c5c92a7941fd8c015a9ae6679ef5,

title = "Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms",

author = "Nicolas Hoertel and Marina S{\'a}nchez-Rico and C{\'e}line Cougoule and Erich Gulbins and Johannes Kornhuber and Alexander Carpinteiro and Becker, {Katrin Anne} and Reiersen, {Angela M.} and Lenze, {Eric J.} and David Seftel and C{\'e}dric Lemogne and Fr{\'e}d{\'e}ric Limosin",

note = "Funding Information: NH, MS-R, EG, JK, AC, and FL are inventors on a patent application related to methods of treating COVID-19, filled by Assistance Publique —Hopitaux de Paris in France. NH has received personal fees and nonfinancial support from Lundbeck, outside the submitted work. AMR and EJL are inventors on a patent application related to methods of treating COVID-19, which was filed by Washington University in St. Louis. EJL has received consulting fees from Johnson and Johnson, and Jazz Pharmaceuticals. AMR has received grant or research support from the McDonnell Center for Systems Neuroscience, the McDonnell Center for Cellular and Molecular Neurobiology, and the Taylor Family Institute for Innovative Psychiatric Research. DS is the Chief Medical Officer and CEO of Enable Biosciences, a CLIA certified Federal clinical reference laboratory that performs COVID-19 antibody testing. CL reports personal fees and nonfinancial support from Janssen-Cilag, Lundbeck, Otsuka Pharmaceutical, and Boehringer Ingelheim, outside the submitted work. FL has received speaker and consulting fees from Janssen-Cilag, Euth{\'e}rapie-Servier, and Lundbeck, outside the submitted work. Other authors declare no competing interests related to this work.",

year = "2021",

month = dec,

doi = "10.1038/s41380-021-01254-3",

language = "English",

volume = "26",

pages = "7098--7099",

journal = "Molecular Psychiatry",

issn = "1359-4184",

number = "12",

}

Hoertel, N, Sánchez-Rico, M, Cougoule, C, Gulbins, E, Kornhuber, J, Carpinteiro, A, Becker, KA, Reiersen, AM , Lenze, EJ, Seftel, D, Lemogne, C & Limosin, F 2021, 'Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms', Molecular Psychiatry, vol. 26, no. 12, pp. 7098-7099. https://doi.org/10.1038/s41380-021-01254-3

TY - JOUR

T1 - Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19

T2 - current evidence and potential mechanisms

AU - Hoertel, Nicolas

AU - Sánchez-Rico, Marina

AU - Cougoule, Céline

AU - Gulbins, Erich

AU - Kornhuber, Johannes

AU - Carpinteiro, Alexander

AU - Becker, Katrin Anne

AU - Reiersen, Angela M.

AU - Lenze, Eric J.

AU - Seftel, David

AU - Lemogne, Cédric

AU - Limosin, Frédéric

N1 - Funding Information: NH, MS-R, EG, JK, AC, and FL are inventors on a patent application related to methods of treating COVID-19, filled by Assistance Publique —Hopitaux de Paris in France. NH has received personal fees and nonfinancial support from Lundbeck, outside the submitted work. AMR and EJL are inventors on a patent application related to methods of treating COVID-19, which was filed by Washington University in St. Louis. EJL has received consulting fees from Johnson and Johnson, and Jazz Pharmaceuticals. AMR has received grant or research support from the McDonnell Center for Systems Neuroscience, the McDonnell Center for Cellular and Molecular Neurobiology, and the Taylor Family Institute for Innovative Psychiatric Research. DS is the Chief Medical Officer and CEO of Enable Biosciences, a CLIA certified Federal clinical reference laboratory that performs COVID-19 antibody testing. CL reports personal fees and nonfinancial support from Janssen-Cilag, Lundbeck, Otsuka Pharmaceutical, and Boehringer Ingelheim, outside the submitted work. FL has received speaker and consulting fees from Janssen-Cilag, Euthérapie-Servier, and Lundbeck, outside the submitted work. Other authors declare no competing interests related to this work.

PY - 2021/12

Y1 - 2021/12

UR - http://www.scopus.com/inward/record.url?scp=85112678595&partnerID=8YFLogxK

U2 - 10.1038/s41380-021-01254-3

DO - 10.1038/s41380-021-01254-3

M3 - Letter

C2 - 34385600

AN - SCOPUS:85112678595

SN - 1359-4184

VL - 26

SP - 7098

EP - 7099

JO - Molecular Psychiatry

JF - Molecular Psychiatry

IS - 12

ER -

Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms

Access to Document

Other files and links

Cite this